In collaboration with the Botulinum Research Center (BRC; Dartmouth, MA, USA) at University of Massachusetts (UMass), Quanterix (Cambridge, MA, USA) will develop and validate a high sensitivity assay capable of measuring extremely low levels of the BoNT agent. The new generation of molecular diagnostic tests is based on Single Molecule Array (SiMoA) technology.

Quanterix was awarded a one year USD 250,155 contract from the Department of Homeland Security (DHS) to develop an assay capable of detecting single molecules of botulinum toxin (BoNT) within complex environmental samples.

Dr. David Hodge from DHS commented, "Quanterix's technology is expected to address a number of challenges currently faced by DHS for identifying active agents of bioterrorism, and offers great promise for a variety of applications in both the private and public sectors."

Quanterix Corporation is developing its proprietary SiMoA technology for the in vitro diagnostics and life science research markets. SiMoA will enable investigators in life science to validate novel, low abundance biomolecules from a single droplet of blood, leading to greater insight into disease detection, diagnosis, therapy selection, and disease monitoring.

The Botulinum Research Center has an international advisory board consisting of scientists from the UK, Japan, Italy, Germany, and the United States.

BRC promotes studies to create an understanding of the botulinum neurotoxins, their applications, and the defenses against such toxins as biothreat agents.

Related Links:
Botulinum Research Center
Quanterix
Department of Homeland Security